Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy RGNT?
Regentis Biomaterials announced the appointment of Dr. Galit Reske as Chief Medical Officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clinical operations across the United States, Europe, and Israel, with a particular focus on cartilage repair and osteochondral treatments. From 2017 to 2026, Dr. Reske served as Director of Clinical Operations at CartiHeal, where she played a central role in the clinical and regulatory advancement of Agili-C, a novel cartilage and osteochondral repair implant.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNT
About RGNT
Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regentis Biomaterials Financial Overview and IPO Pricing
- Operating Expense Management: For the year ending December 31, 2025, Regentis reported operating expenses of $7.0 million, with $5.3 million attributed to non-cash expenses, indicating prudent cash management while advancing clinical developments, thus ensuring financial stability.
- Cash Flow Position: As of December 31, 2025, Regentis had $7.4 million in cash and equivalents, providing sufficient runway to support patient enrollment and site expansion for its pivotal Phase III trial, thereby ensuring the continuity of its projects.
- IPO Pricing Announcement: Regentis Biomaterials has priced its initial public offering at $10 million, which will provide essential funding for subsequent research and market promotion, enhancing the company's competitive position in the market.
- Clinical Trial Progress: The company is advancing its pivotal clinical trial for GelrinC in knee cartilage repair, and successful trial outcomes will lay the groundwork for future product launches, further elevating the company's standing in the industry.
See More
Regentis Biomaterials Appoints New CFO Ahead of IPO
- Executive Appointment: Regentis Biomaterials has appointed Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately, aiming to strengthen the company's financial and business strategy ahead of the upcoming European launch of GelrinC.
- Product Launch Preparation: Gon's appointment coincides with Regentis's preparations for the European market launch of GelrinC following CE Mark approval, which is expected to generate new revenue streams and enhance market competitiveness.
- Clinical Trial Progress: Regentis is also advancing its Phase III FDA trial for GelrinC in the U.S., and Gon's financial expertise will help manage cash flow effectively, ensuring the trial proceeds smoothly.
- IPO Plans: Regentis Biomaterials has announced an initial public offering priced at $10 million, and Gon's addition is expected to support the company's performance in the capital markets, bolstering investor confidence.
See More
Regentis Appoints New CFO to Drive GelrinC Commercialization
- Leadership Strengthening: Regentis Biomaterials has appointed Ori Gon as CFO and Chief Business Officer, bringing over 15 years of experience in medtech and capital markets, which will be crucial as the company transitions towards commercialization.
- Significant Product Progress: GelrinC® has received CE Mark approval in Europe and is currently in a pivotal Phase III FDA trial in the U.S., with over 50% enrollment completed, which is expected to create substantial market opportunities for the company.
- Large Market Potential: GelrinC® addresses an annual market of approximately 470,000 cases for knee cartilage repair in the U.S., offering an innovative cell-free hydrogel implant that fills the current gap of effective treatments available on the market.
- Strategic Partnership Opportunities: Gon’s appointment will assist the company in evaluating strategic partnerships to support the launch of GelrinC® in Europe and lay the groundwork for sustainable revenue growth, enhancing the company's competitiveness in the medical market.
See More
Regentis Biomaterials Stock Surges Nearly 15% Amid 2,990% Follower Increase on Stocktwits
- Follower Surge: Regentis Biomaterials experienced a staggering 2,990% increase in followers on Stocktwits over the past month, indicating strong retail investor interest that could drive future stock price growth.
- Stock Performance: The company's shares rose 5% in after-market trading on Thursday, poised for a fourth consecutive day of gains, reflecting optimistic market sentiment and positioning for its best week since the December IPO.
- Clinical Trial Progress: Regentis's GelrinC is currently undergoing a Phase III FDA study aimed at supporting future market approval, with recent results showing a significant average MOCART score improvement to 88.8 after 24 months, indicating near-complete structural repair.
- Patent Protection: The company received a patent for GelrinC from the U.S. Patent and Trademark Office in December, focusing on its ready-to-use liquid formulation, which aims to simplify surgical procedures and enhance patient experience, further solidifying its market competitiveness.
See More
Regentis Biomaterials Closes IPO Raising $10 Million
- Successful IPO: Regentis Biomaterials has successfully completed its initial public offering of 1.25 million ordinary shares at $8.00 per share, raising a total of $10 million, which significantly strengthens the company's financial position for future growth.
- Clear Use of Proceeds: The funds raised will primarily be allocated for completing pivotal clinical trials and preparing the PMA submission for GerlinC, as well as repaying certain debts and deferred compensation payments, ensuring the company's financial health.
- Market Trading Launch: The ordinary shares began trading on the NYSE American on December 4, 2025, under the ticker symbol “RGNT”, marking the company's official entry into the capital markets, which will enhance brand visibility and market credibility.
- Strategic Development Focus: Regentis is dedicated to developing orthopedic treatment solutions based on degradable hydrogel implants and plans to commercialize its products in Europe, further expanding its market share in the regenerative medicine sector.
See More
Regentis Biomaterials Prices IPO at $8.00 per Share, Raising $10 Million
- IPO Pricing: Regentis Biomaterials has priced its initial public offering at $8.00 per share for 1,250,000 ordinary shares, aiming to raise a total of $10 million, reflecting the company's market appeal in the regenerative medicine sector.
- Underwriter Selection: ThinkEquity has been appointed as the sole book-running manager for the offering, indicating strong professional support in capital markets and enhancing investor confidence.
- Use of Proceeds: The company intends to utilize the net proceeds primarily for development activities, including completing its pivotal trial and preparing the PMA submission for GerlinC, while also addressing debt repayment and deferred compensation, showcasing a clear strategic focus on future growth.
- Trading Launch Date: The ordinary shares are expected to begin trading on the NYSE American on December 4, 2025, with the offering anticipated to close on December 5, marking a significant milestone for the company in the capital markets.
See More
Regentis Biomaterials Financial Overview and IPO Pricing
- Operating Expense Management: For the year ending December 31, 2025, Regentis reported operating expenses of $7.0 million, with $5.3 million attributed to non-cash expenses, indicating prudent cash management while advancing clinical developments, thus ensuring financial stability.
- Cash Flow Position: As of December 31, 2025, Regentis had $7.4 million in cash and equivalents, providing sufficient runway to support patient enrollment and site expansion for its pivotal Phase III trial, thereby ensuring the continuity of its projects.
- IPO Pricing Announcement: Regentis Biomaterials has priced its initial public offering at $10 million, which will provide essential funding for subsequent research and market promotion, enhancing the company's competitive position in the market.
- Clinical Trial Progress: The company is advancing its pivotal clinical trial for GelrinC in knee cartilage repair, and successful trial outcomes will lay the groundwork for future product launches, further elevating the company's standing in the industry.
See More
Regentis Biomaterials Appoints New CFO Ahead of IPO
- Executive Appointment: Regentis Biomaterials has appointed Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately, aiming to strengthen the company's financial and business strategy ahead of the upcoming European launch of GelrinC.
- Product Launch Preparation: Gon's appointment coincides with Regentis's preparations for the European market launch of GelrinC following CE Mark approval, which is expected to generate new revenue streams and enhance market competitiveness.
- Clinical Trial Progress: Regentis is also advancing its Phase III FDA trial for GelrinC in the U.S., and Gon's financial expertise will help manage cash flow effectively, ensuring the trial proceeds smoothly.
- IPO Plans: Regentis Biomaterials has announced an initial public offering priced at $10 million, and Gon's addition is expected to support the company's performance in the capital markets, bolstering investor confidence.
See More
Regentis Appoints New CFO to Drive GelrinC Commercialization
- Leadership Strengthening: Regentis Biomaterials has appointed Ori Gon as CFO and Chief Business Officer, bringing over 15 years of experience in medtech and capital markets, which will be crucial as the company transitions towards commercialization.
- Significant Product Progress: GelrinC® has received CE Mark approval in Europe and is currently in a pivotal Phase III FDA trial in the U.S., with over 50% enrollment completed, which is expected to create substantial market opportunities for the company.
- Large Market Potential: GelrinC® addresses an annual market of approximately 470,000 cases for knee cartilage repair in the U.S., offering an innovative cell-free hydrogel implant that fills the current gap of effective treatments available on the market.
- Strategic Partnership Opportunities: Gon’s appointment will assist the company in evaluating strategic partnerships to support the launch of GelrinC® in Europe and lay the groundwork for sustainable revenue growth, enhancing the company's competitiveness in the medical market.
See More
Regentis Biomaterials Stock Surges Nearly 15% Amid 2,990% Follower Increase on Stocktwits
- Follower Surge: Regentis Biomaterials experienced a staggering 2,990% increase in followers on Stocktwits over the past month, indicating strong retail investor interest that could drive future stock price growth.
- Stock Performance: The company's shares rose 5% in after-market trading on Thursday, poised for a fourth consecutive day of gains, reflecting optimistic market sentiment and positioning for its best week since the December IPO.
- Clinical Trial Progress: Regentis's GelrinC is currently undergoing a Phase III FDA study aimed at supporting future market approval, with recent results showing a significant average MOCART score improvement to 88.8 after 24 months, indicating near-complete structural repair.
- Patent Protection: The company received a patent for GelrinC from the U.S. Patent and Trademark Office in December, focusing on its ready-to-use liquid formulation, which aims to simplify surgical procedures and enhance patient experience, further solidifying its market competitiveness.
See More
Regentis Biomaterials Closes IPO Raising $10 Million
- Successful IPO: Regentis Biomaterials has successfully completed its initial public offering of 1.25 million ordinary shares at $8.00 per share, raising a total of $10 million, which significantly strengthens the company's financial position for future growth.
- Clear Use of Proceeds: The funds raised will primarily be allocated for completing pivotal clinical trials and preparing the PMA submission for GerlinC, as well as repaying certain debts and deferred compensation payments, ensuring the company's financial health.
- Market Trading Launch: The ordinary shares began trading on the NYSE American on December 4, 2025, under the ticker symbol “RGNT”, marking the company's official entry into the capital markets, which will enhance brand visibility and market credibility.
- Strategic Development Focus: Regentis is dedicated to developing orthopedic treatment solutions based on degradable hydrogel implants and plans to commercialize its products in Europe, further expanding its market share in the regenerative medicine sector.
See More
Regentis Biomaterials Prices IPO at $8.00 per Share, Raising $10 Million
- IPO Pricing: Regentis Biomaterials has priced its initial public offering at $8.00 per share for 1,250,000 ordinary shares, aiming to raise a total of $10 million, reflecting the company's market appeal in the regenerative medicine sector.
- Underwriter Selection: ThinkEquity has been appointed as the sole book-running manager for the offering, indicating strong professional support in capital markets and enhancing investor confidence.
- Use of Proceeds: The company intends to utilize the net proceeds primarily for development activities, including completing its pivotal trial and preparing the PMA submission for GerlinC, while also addressing debt repayment and deferred compensation, showcasing a clear strategic focus on future growth.
- Trading Launch Date: The ordinary shares are expected to begin trading on the NYSE American on December 4, 2025, with the offering anticipated to close on December 5, marking a significant milestone for the company in the capital markets.
See More
